Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, T-Cell, Cutaneous 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Mycosis Fungoides 3Leukemia-Lymphoma, Adult T-Cell 3Sezary Syndrome 2Recurrence 2Lymphoma, T-Cell, Peripheral 2Neoplasms 1Lymphoma, T-Cell 1Lymphoma 1Leukemia, T-Cell 1Hematologic Neoplasms 1

Interventions

Gemcitabine 53Bevacizumab 52Cyclophosphamide 49Docetaxel 42Carboplatin 40pembrolizumab 37Paclitaxel 36Fluorouracil 36Cisplatin 35Radiotherapy 31Oxaliplatin 31Capecitabine 29Irinotecan 28Dexamethasone 27Leucovorin 25Cetuximab 25Nivolumab 24Doxorubicin 22Drug Therapy 21Erlotinib Hydrochloride 20Pemetrexed 19durvalumab 18trametinib 17fludarabine 16atezolizumab 16Trastuzumab 16Sunitinib 16Rituximab 16Prednisone 16Sorafenib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms × mogamulizumab × Clear all
NCT01611142 2024-06-17

Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL)

Kyowa Kirin Co., Ltd.

Phase 2 Completed
38 enrolled
LymphoidOther hematologic neoplasm

Neoplasms, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡